Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

O. Rosas, Iván; Bräu, Norbert; R. Waters, Michael; C. Go, Ronaldo; D. Hunter, Bradley; Bhagani, Sanjay; J. Skiest, Daniel; Aziz, Mariam; Cooper, Nichola; S. Douglas, Ivor; Savic, Sinisa; Youngstein, Taryn; Del Sorbo, Lorenzo; Cubillo Gracián, Antonio; J. De La Zerda, David; Ustianowski, Andrew; Bao, Min; Dimonaco, Sophie; Graham, Emily; Matharu, Balpreet; Spotswood, Helen; Tsai, Larry; Malhotra, Atul

doi:10.1056/nejmoa2028700

Public

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Published in New England Journal of Medicine • Feb 25, 2021

Authors:

Iván O. Rosas

Norbert Bräu

Michael R. Waters

Abstract

BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 p...

Subject

Tocilizumab

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!